AF
TRVI icon

Allworth Financial’s Trevi Therapeutics TRVI Stock Holding History

Allworth Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
766
-1
-0.1% -$15 ﹤0.01% 3462
2026
Q1 		$9.15K Buy
767
+14
+2% +$157 ﹤0.01% 3573
2025
Q4 		$9.43K Buy
753
+700
+1,321% +$8.09K ﹤0.01% 3311
2025
Q3 		$485 Buy
+53
New +$397 ﹤0.01% 4438
2025
Q2 		– Sell
-20
Closed -$127 – 4671
2025
Q1 		$127 Buy
+20
New +$95 ﹤0.01% 3932

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Allworth Financial's TRVI Position: Q2 2026 in Review

Allworth Financial reduced its Trevi Therapeutics (TRVI) stake by 0.13% in Q2 2026, selling an estimated $15 and leaving 766 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3462.

Allworth Financial first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Allworth Financial held 766 shares of Trevi Therapeutics worth $14.3K as of Q2 2026.
  • Allworth Financial sold 1 Trevi Therapeutics share in Q2 2026, an estimated $15.
  • Trevi Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3462 holding.
  • Allworth Financial first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.